

COMPANY OVERVIEW

DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a "first-in-class" small molecule chemotherapy that is currently being evaluated in a Phase 2 clinical trial for the treatment of refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 as a therapy for front-line GBM and solid tumors, including non-small cell lung cancer (NSCLC) and ovarian cancer.

RECENT NEWS

DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM

Apr 17 2018, 2:00 PM EDT

DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research

Apr 16 2018, 9:00 AM EDT

DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results

Feb 14 2018, 5:39 PM EST

STOCK OVERVIEW

Symbol	DMPI
Exchange	NASDAQ
Shares OS	21,927,517
Market Cap	\$19.95M
Last Price	\$0.91
52-Week Range	\$0.78 - \$2.85

INVESTOR RELATIONS

T: (604) 629-5989
ir@delmarpharma.com

MANAGEMENT TEAM

Saiid Zarrabian

Interim President & Interim Chief Executive Officer

Dennis Brown

Chief Scientific Officer

Scott Prail

Chief Financial Officer

DELMAR PHARMACEUTICALS, INC.

Corporate

Suite 720 - 999 West Broadway
Vancouver, BC V5Z 1K5
CA

Clinical Operations

3475 Edison Way
Suite R
Menlo Park, CA 94025
USA

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.